Consolidated Financial Summary for the Fiscal Year Ending July 2026 (Japanese GAAP)

Overview of Results

Under the Mid-Term Management Plan 2026, the Group is promoting the 1K Value Creation project. Development of a new electrode material following Ovoveil, an eggshell membrane material, continues in the drug discovery space with cancer-related antibodies and peptide drugs. New products include expansion of the Neumo series and deployment of Neumo D, plus enhanced sales of Pharma Gaba in North America and Thailand. The financial summary reports sales of 63,223 million yen, operating income of 2,632 million yen, and net income attributable to owners of the parent of 1,988 million yen, marking a substantial increase in net income, while ordinary income declined year over year. R&D investment reached 1,858 million yen and advertising expense was 33,917 million yen, down from the previous period. Full-year guidance projects sales of 64,000 million yen, operating income of 3,000 million yen, and net income of 2,200 million yen.

Trends by Segment and Financial Impact

BtoB remains steady, including functional materials, CMO, and CHC. BtoC sales of pharmaceuticals, quasi-drug products, cosmetics, and supplements are solid, with new products such as Neumo hair-growth products contributing. The Biomedicals segment includes antibody drugs and proteome analysis support. Overall, new product launches and overseas expansion drive profit growth, while ordinary income shows a downward trend.